Source comparison
Comparison: Tesamorelin vs Other GH Secretagogues
Tesamorelin popular in research when compared to alternatives becomes clear when mechanisms are mapped side-by-side. Tesamorelin GHRH receptor (pituitary somatotrophs) ~26 minutes Pulsatile (mimics natural episodic release) None. Does not bind GHSR-1a Neutral
This comparison does not assign a generated winner or score.
- Tesamorelin popular in research when compared to alternatives becomes clear when mechanisms are mapped side-by-side.
- Tesamorelin
- GHRH receptor (pituitary somatotrophs)
- ~26 minutes
- Pulsatile (mimics natural episodic release)
- None. Does not bind GHSR-1a
- Neutral at therapeutic doses
- Low. Endogenous feedback intact
- GHRP-2
- Ghrelin receptor (GHSR-1a) + unknown GHS receptor
- ~30 minutes
- Pulsatile but with orexigenic signaling
- High. Stimulates appetite, gastric motility
- May impair glucose tolerance at high doses
- Moderate. Receptor downregulation observed >12 weeks
- Ipamorelin
- Ghrelin receptor (GHSR-1a) selective
- ~2 hours
- Pulsatile with minimal cortisol/prolactin co-release
- Moderate. Less pronounced than GHRP-2
- Minimal at doses <300 mcg
- Moderate. Tachyphylaxis reported
- CJC-1295 (DAC)
- GHRH receptor with albumin binding
- 6–8 days
- Sustained elevation (non-pulsatile)
- None
- Neutral initially; long-term data limited
- High. Continuous receptor occupancy
- Exogenous GH (somatropin)
- GH receptor (direct agonist)
- 3–4 hours (subcutaneous)
- Continuous supraphysiological elevation
- Impairs insulin signaling at >2 IU/day chronically
- N/A. Replaces rather than stimulates endogenous GH
- Assessment
- Tesamorelin offers the most physiologically aligned GH stimulation profile: pulsatile secretion, no ghrelin cross-reactivity, preserved insulin sensitivity, and low desensitisation risk. GHRP compounds are effective but carry appetite/metabolic trade-offs. CJC-1295 DAC's extended half-life disrupts natural rhythm. Direct GH risks metabolic side effects and shuts down endogenous production.